
Clinical trials targeting Lp(a)
Until recent years, Lp(a) has lagged behind other atherogenic lipoproteins in the development of targeted lipid lowering therapies. That is now changing, as Professor Ioanna Gouni-Berthold, University of Cologne, Germany explains.